Claims

1. Use of Compound A:



Compound A

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of pancreatic cancer in a human subject in need thereof, wherein 10 mg to 500 mg of Compound A is to be orally administered to the subject daily.

2. The use of claim 1, wherein 120 mg to 500 mg of Compound A is to be administered to the subject.

3. The use of claim 1, wherein 160 mg to 500 mg of Compound A is to be administered to the subject.

4. The use of claim 1, wherein 250 mg to 500 mg of Compound A is to be administered to the subject.

5. The use of claim 1, wherein 300 mg to 500 mg of Compound A is to be administered to the subject.

6. The use of claim 1, wherein 400 mg to 500 mg of Compound A is to be administered to the subject.

7. The use of claim 1 or claim 2, wherein 120 mg of Compound A is to be administered to the subject.

8. The use of any one of claims 1 to 3, wherein 160 mg of Compound A is to be administered to the subject.

9. The use of any one of claims 1 to 3, wherein 200 mg of Compound A is to be administered to the subject.

10. The use of any one of claims 1 to 4, wherein 250 mg of Compound A is to be administered to the subject.

11. The use of any one of claims 1 to 5, wherein 300 mg of Compound A is to be administered to the subject.

12. The use of any one of claims 1 to 5, wherein 350 mg of Compound A is to be administered to the subject.

13. The use of any one of claims 1 to 6, wherein 400 mg of Compound A is to be administered to the subject.

14. The use of any one of claims 1 to 6, wherein 450 mg of Compound A is to be administered to the subject.

15. The use of any one of claims 1 to 6, wherein 500 mg of Compound A is to be administered to the subject.

16. The use of any one of claims 1 to 15, wherein Compound A is to be administered to the subject once per day.

17. The use of any one of claims 1 to 16, wherein Compound A is to be administered 1, 2, 3, 4, 5, 6 or 7 times per week.

18. The use of any one of claims 1 to 17, wherein the subject is to be administered Compound A for at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, at least 15 months, at least 18 months, at least 21 months, or at least 23 months.

19. The use of any one of claims 1 to 18, wherein Compound A is to be administered in treatment cycles and each treatment cycle is 7 days, 14 days, 21 days, 28 days, 1 month, 2 months, 3 months, 4 months, 5 month, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 1 year.

20. The use of claim 19, wherein the subject undergoes 1, 2, 3, or more treatment cycles.

21. The use of any one of claims 1 to 20, wherein the pancreatic cancer comprises a RAS mutation.

22. The use of claim 21, wherein the RAS mutation is at position 12, 13, or 61.

23. The use of claim 22, wherein the RAS mutation is a mutation selected from the group consisting of G12C, G12D, G12V, G12R, G12A, G12S, G13C, G13D, and Q61H.

24. The use of claim 1, wherein the pancreatic cancer is pancreatic ductal adenocarcinoma (PDAC).

25. The use of any one of claims 1 to 6, wherein an additional anticancer therapy is to be administered.

26. The use of claim 24, wherein the subject has locally advanced or metastatic PDAC.